Semaglutide (10mg)
Semaglutide is a GLP-1 receptor agonist with a half-life of ~7 days. The 10 mg vial provides more product per vial, reducing cost at maintenance doses. Weekly subcutaneous administration with gradual titration.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
Research monograph
See the full Semaglutide encyclopedia page with mechanism, evidence tier, related variants and research context.
How It Works
Semaglutide is a GLP-1 agonist with 94% homology to human GLP-1. It reduces appetite, slows gastric emptying, and improves glycemic control. Its half-life is ~7 days due to albumin binding.
Quick Start
- Reconstitution: Add 2.0 mL bacteriostatic water → 5.0 mg/mL concentration.
- Weekly range: 0.25–2.4 mg once weekly.
- Storage: Lyophilized: −20 °C; reconstituted: 2–8 °C, within 28 days.
Gradual Titration (2 mL = 5.0 mg/mL)
Route: Subcutaneously | Frequency: Once weekly
| Week | Dose | Units (per injection) |
|---|---|---|
| Weeks 1–4 | 0.25 mg (250 mcg) | 5 Units (0.05 mL) |
| Weeks 5–8 | 0.5 mg (500 mcg) | 10 Units (0.10 mL) |
| Weeks 9–12 | 1.0 mg | 20 Units (0.20 mL) |
| Weeks 13–16 | 1.7 mg | 34 Units (0.34 mL) |
| Weeks 17+ (Maintenance) | 2.4 mg | 48 Units (0.48 mL) |
Studies report administration once weekly on the same day. The higher concentration (5 mg/mL) reduces injection volumes by half compared to the 5 mg vial. One 10 mg vial is sufficient for ~4 weeks of maintenance at 2.4 mg/week.
Related compounds
Reconstitution Steps
- Draw 2.0 mL of bacteriostatic water.
- Inject slowly down the side of the vial; avoid foaming.
- Swirl gently until dissolved.
- Note the date; refrigerate at 2–8 °C.
- Use within 28 days.
Protocol Overview
- Objective: Chronic weight management via GLP-1 activation.
- Schedule: Weekly injections for 16–20+ weeks.
Dosing Protocol
- Wk 1–4: 0.25 mg/wk.
- Wk 5–8: 0.5 mg/wk.
- Wk 9–12: 1.0 mg/wk.
- Wk 13–16: 1.7 mg/wk.
- Wk 17+: 2.4 mg/wk (maintenance).
- Break between cycles: After completing a cycle, a 4–8 week washout period is recommended before repeating. Semaglutide has a long half-life (~7 days)—the body needs time to fully clear the peptide and restore natural GLP-1 regulation.
Washout & Cycle Restart
When can I restart?
After completing a cycle, a 4–8 week washout period is recommended before repeating. Semaglutide has a long half-life (~7 days)—the body needs time to fully clear the peptide and restore natural GLP-1 regulation.
Minimum wait period: 4 weeks
Storage Instructions
- Lyophilized: −20 °C.
- Reconstituted: 2–8 °C; use within 28 days; do not freeze.
Important Notes
- If a dose is missed, take it within 5 days.
- Gradual titration reduces GI side effects.
Potential Benefits & Side Effects
Potential Benefits:
- Weight loss of 10–15% of body weight.
- Improved glycemic control.
- Cardiovascular benefits.
- Fewer vials needed for long-term use.
Potential Side Effects:
- GI: nausea, vomiting, diarrhea — typically mild.
- Injection site reactions.
- Rare: pancreatitis, cholelithiasis.
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Thyroid C-cell tumors (medullary thyroid carcinoma)
In rodents, semaglutide caused dose-dependent thyroid C-cell tumors (medullary carcinoma). Contraindicated in patients with personal/family history of MTC or MEN 2.
📄 FDA Boxed Warning — Ozempic® / Wegovy® LabelAcute pancreatitis
Reports of acute pancreatitis, including necrotizing. Discontinue if suspected. Increased risk with history of pancreatitis.
📄 FDA Label — Ozempic®Cholelithiasis & cholecystitis
Increased risk of gallstones due to rapid weight change. 1.5–3% incidence in clinical trials.
📄 STEP Trials — NEJM 2021References
- PMC – Semaglutide for Weight — Mechanism and efficacy
View Source - NCBI Bookshelf – StatPearls — Semaglutide pharmacology
View Source - Mayo Clinic — Semaglutide clinical guidance
View Source
Recommended Supplements
Vitamin B12 (Methylcobalamin)
Vitamin D3 + K2
Omega-3 Fish Oil (EPA/DHA)
Protein / Collagen
Fiber Supplement (Psyllium)
External Sources & Regulatory Status
Regulatory Approvals
Ozempic® / Wegovy® · Type 2 diabetes / Obesity (2017)
Ozempic® / Wegovy® · Type 2 diabetes / Obesity (2018)
Ozempic® · Type 2 diabetes (2018)
Ozempic® · Type 2 diabetes (2021)
Ozempic® / Wegovy® · Type 2 diabetes / Obesity (2019)
Ozempic® / Wegovy® · Type 2 diabetes / Obesity (2018)
Ozempic® / Wegovy® · Type 2 diabetes / Obesity (2019)
Approved worldwide (7+ countries)
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →